ULTRAGENYX PHARMACEUTICAL INC. Fair Value Adjustment of Warrants
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2017-02-17
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for fiscal 2016 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for fiscal 2014 was $3.32M, a 14.58% increase from fiscal 2013.
- ULTRAGENYX PHARMACEUTICAL INC. fair value adjustment of warrants for fiscal 2013 was $2.90M, a 860.60% increase from fiscal 2012.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 47 month |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-17 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-02-17 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-12 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $0.00 derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $3.32M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $3.32M 10-Q · filed 2015-11-10 | $5.15M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $3.32M 10-Q · filed 2015-08-14 | $5.15M derived: sum of 3 quarters · filed 2016-02-26 | $5.85M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $3.32M 10-Q · filed 2015-05-12 | $5.15M derived: sum of 2 quarters · filed 2016-02-26 | $5.85M derived: sum of 3 quarters · filed 2016-02-26 | $6.23M derived: sum of 4 quarters · filed 2016-02-26 | $6.54M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $2.53M derived: sum of 2 quarters · filed 2016-02-26 | $2.90M derived: sum of 3 quarters · filed 2016-02-26 | $2.90M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.08M derived: sum of 2 quarters · filed 2014-11-10 | $1.08M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $372.00K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | -$2.00K 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $302.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |